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Dear Editor
A Proposal of Guidance for Identification
of Schizophyllum commune-Associated
Sinobronchial Allergic Mycosis
Our recent studies suggested that Schizophyllum com-
mune, which is a basidiomycetous (BM) fungus that
can cause allergic bronchopulmonary mycosis
(ABPM)1 and allergic fungal rhinosinusitis (AFRS),2
is an important organism that acts as a causative fun-
gal antigen and is a candidate organism influencing
the clinical manifestations of asthma via sensitization
to this fungus.3 This environmental fungus is likely to
be closely related to allergic fungal respiratory dis-
ease (AFRD).
When unknown samples or plural eumycetes are
cultured from bronchial materials from patient with
mucoid impaction of the bronchi (MIB), a definitive
diagnosis of ABPM cannot be made without positive
findings of an allergic reaction against the identified
fungi.4 Similarly, a positive allergic reaction is neces-
sary to make a definite diagnosis of AFRS in patients
with chronic rhinosinusitis (CRS). Antigen inhalation
test for definitive diagnosis of ABPM caused by S.
commune is not commonly used in most clinics; how-
ever, even skin tests cannot be performed easily with-
out use of S. commune antigenic solution. Therefore,
some authors have proposed removing type I hyper-
sensitivity from the diagnostic criteria for AFRS.5
Based on the concept of “one airway one disease”
in fungal allergy, we assume that one fungal antigen
causes both AFRS and ABPM. Historically, the term
sinobronchial allergic mycosis (SAM)6 coined by Ve-
narske and deShazo is close to this concept. Patients
with SAM have chronic sinusitis involving multiple si-
nuses, asthma, immediate cutaneous reactivity to fun-
gal allergens, peripheral eosinophilia, and radio-
graphic evidence of bronchiectasis. Total serum IgE
levels are also usually elevated, and a variety of chest
radiographic abnormalities may occur, ranging from
mass lesions to diffuse pulmonary infiltrates and even
normal findings on chest radiography.
Recently, we reported a case of ABPM caused by
S. commune7 in accordance with the definitive diag-
nostic process, including antigen inhalation test.4 In
this case, antifungal drug showed sufficient efficacy
against both MIB and fluid collection in the maxilla
sinus. Despite the possibility of concomitant ABPM
and AFRS caused by the same fungus, a diagnosis of
SAM was not made in this case because of the lack of
a final diagnosis of AFRS caused by this fungus.
Thus, SAM is reasonable as a theoretical concept, but
there is often difficulty in separately investigating the
allergological reactions that arise in the upper and
lower airways in clinical practice.
Singh et al. 8 reported that the ratio of non-
sporulating molds (NSM), especially BM fungi, iso-
lated from 4948 respiratory specimens was 1.05%, and
the etiological fungi in 8 case of ABPM were all re-
vealed to be S. commune. Chowdhary et al.9 reported
that S. commune was the third most common major
causative antigen (11%) in 143 cases of ABPM due to
fungi other than Aspergillus.
Considering both the high prevalence of this fun-
gus in ABPM8,9 and the fundamental similarity in
therapy for both disorders occurring in the same indi-
vidual, it will be helpful to make simplified guidance
for S. commune-associated SAM from the viewpoint
of Schizophyllum allergy.
The allergological findings related to S. commune
in patients (n = 13) with definitive diagnosis of ABPM
are shown in Table 1. Due to the high sensitivity and
specificity of S. commune-specific IgE (Phadia Ltd. ,
Uppsala, Sweden ) in these patients, S. commune-
specific IgE is considered to be reliable as a substi-
tute allergological marker for the antigen inhalation
test.
It may be controversial whether the coined SAM is
really an appropriate term for representing this dis-
ease condition of AFRD, and we tentatively propose
the following guidance for S. commune-associated
SAM : Fundamental condition of the patient : 1 )
eosinophilic MIB withwithout asthma andor 2 )
eosinophilic mucin involved in multiple sinuses with
without nasal polyposis ; Major criteria : 1 ) positive
fungal culture of S. commune from bronchial speci-
mens or sinus contents, and 2) positive results for S.
commune-specific IgE andor S. commune-specific
IgG; Supplemental findings: 1) elevated peripheral
eosinophils andor total serum IgE levels, and 2) ra-
diographic evidence of ABPM andor AFRS.
Thus, when S. commune is detected from bronchial
or nasal specimens in patients with MIB or CRS, it is
recommended to investigate these patients in accor-
dance with the above guidance for S. commune-
associated SAM. This disease concept would attract
attention to the coexistence of other diseases that
may have been overlooked or treated separately. Rec-
ognition of S. commune-associated SAM would help
to accumulate data for patients and subsequently es-
tablish treatment strategies for Schizophyllum allergy
from the viewpoint of one airway one disease. The
previously proposed four-step treatment strategy for
ABPM 4 would be applicable for S. commune-
associated SAM: 1) prevention and eradication of fun-
gal colonization in the airway; 2) control of eosino-
philic bronchitis caused by fungal exposure; 3) re-
moval of any mucus plugs from the airway; and 4) ef-
fective management of environmental fungi.
Clarification of both characteristics of S. commune
as a mushroom spore and the ecology of this mush-
room growing in the forest may provide new insights
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Table　1　Allergological fi ndings of Schizophyllum commune in patients with ABPM
The results of allergological fi ndings against Schizophyllum commune in the patients with ABPM
ABPM caused by S. commune
n = 4
ABPM caused by fungi other than S. commune
n = 9
S. commune-specifi c IgG (4/4) (4/9)
S. commune-specifi c IgE (4/4) (0/9)
Positive results of immediate skin test (2/2) (2/8)
ABPM, allergic bronchopulmonary mycosis.
ABPM caused by S. commune was diagnosed in accordance with the defi nitive diagnostic process including antigen inhalation test.
The Phadia (previously Pharmacia) CAP system was used to quantify specifi c IgG and IgE levels (Phadia Ltd.). A positive test was taken 
as a measurement >2.00 (mgA/L) and >0.35 (UA/mL), respectively.
to prevent disease recrudescence. The high suscepti-
bility of S. commune to antifungal drugs10 would pro-
vide benefits in patients with AFRD. Furthermore, pe-
riodic surveys of S. commune, which is usually not
present indoors, may be helpful as a preventive strat-
egy.
The development of more convenient methods for
identifying S. commune and for investigating S.
commune-specific IgE would lead to the wide accep-
tance of S. commune-associated AFRD among clinical
immunologists and allergists.
ACKNOWLEDGEMENTS
Authors’ contributions: HO, NO and KM belong to
Fungus-associated cough research society ( FACS-
JAPAN) . Especially KM contributes to identifying
fungi. MF is general conductor of this study.
The authors wish to thank Dr. Kazuo Akiyama (Clini-
cal Research Center for Allergy and Rheumatology,
National Hospital Organization, Sagamihara National
Hospital, Kanagawa, Japan) for preparing the anti-
genic solution.
Haruhiko Ogawa1, Masaki Fujimura2,
Noriyuki Ohkura3 and Koichi Makimura4
1 Division of Pulmonary Medicine, Ishikawa-ken
Saiseikai Kanazawa Hospital, 2Respiratory Medicine,
National Hospital Organization Nanao Hospital, 3Res-
piratory Medicine, Ishikawa Prefectural Central Hos-
pital, Ishikawa and 4Laboratory of Space and Environ-
mental Medicine, Teikyo University, Tokyo, Japan
Email: saiseikh@po3.nsknet.or.jp
Conflict of interest: No potential conflict of interest
was disclosed.
REFERENCES
1. Kamei K, Unno H, Nagano K, Kuriyama T, Nishimura K,
Miyaji M. Allergic bronchopulomonary mycosis caused
by the basidiomycetous fungus Schizophyllum commune.
Clin Infect Dis 1994;18:305-9.
2. Bent JP III, Kuhn FA. Diagnosis of allergic fungal sinusi-
tis. Otolaryngol Head Neck Surg 1994;111:580-8.
3. Ogawa H, Fujimura M, Takeuchi Y, Makimura K. Two
cases of Schizophyllum asthma: Is this a new clinical en-
tity or a precursor of ABPM? Pulm Pharmacol Ther 2011;
24:559-62.
4. Ogawa H, Fujimura M, Takeuchi Y, Makimura K. The de-
finitive diagnostic process and successful treatment for
ABPM caused by Schizophyllum commune : A report of
two cases. Allergol Int 2012;61:163-9.
5. deShazo RD, Swain RE. Diagnostic criteria for allergic
fungal sinusitis. J Allergy Clin Immunol 1995;96:24-35.
6. Venarske DL, deShazo RD. Sinobronchial allergic myco-
sis. Chest 2002;121:1670-6.
7. Yamamura K, Ohkura N, Ogawa H, Nishikawa S, Kasa-
hara K, Fujimura M. [A case of allergic bronchopulmon-
ary mycosis due to Schizophyllum commune; Possibility of
sinobronchial allergic mycosis (SAM) syndrome]. [J Jap
Resp Soc]. In press (in Japanese).
8. Singh PK, Kathuria S, Agarwal K, Gaur SN, Meis JF,
Chowdhary A. Clinical significance and molecular charac-
terization of non-sporulating moulds isolated from the res-
piratory tract of bronchopulmonary mycoses patients with
special reference to basidiomycetes. J Clin Microbiol
2013;51:3331-7.
9. Chowdhary A, Agarwal K, Kathuria S, Gaur SN, Rand-
hawa HS, Meis JF. Allergic bronchopulmonary mycosis
due to fungi other than Aspergillus: a global overview.
Crit Rev Microbiol 2014;40:30-48.
10. Chowdhary A, Kathuria S, Singh PK et al. Molecular char-
acterization and in vitro antifungal susceptibility profile of
Schizophyllum commune, an emerging basidiomycete in
bronchopulmonary mycoses. Antimicrob Agents Che-
mother 2013;57:2845-8.
